Rheumnow Podcast

Combination Therapy in Rheumatoid Arthritis
Study Design and Comparative Effectiveness in RA
Difficult to Treat RA
What are our goals, really, in ILD
New Treatments in Scleroderma Early Days
A New Way to Measure Disease Activity in Rheumatoid Arthritis

5mg kg HCQ Threshold in SLE Is it Time to Reconsider
Does Scl-Ab change predict pulmonary decline in systemic sclerosis
Does the Air we Breathe Shape Lupus
Four Joint Fibromyalgia Warning
Kidney Transplantation in Lupus
Lupus Control without Steroid Burden
Lupus Remission is not one Single Thing
Mortality and Myositis in ILD
Screen-detected ILD in Scleroderma
Snippets & SNPs in ILD and Fibrosis
When Low Cardiovascular Risk Misses Coronary Plaque

TNFi Failure in PsA to cycle or not cycle
GLP-1 Drugs in Osteoarthritis and Rheumatoid Arthritis
GLP-1s and Obesity in Rheumatic Disease
Long-term Opioid Use in Lupus Does Obesity Play a Role
TRIUMPH-4 Retatrutide GLP-1 in Osteoarthritis
BE BOLD with Professor McInnes
Can Tirzepatide Lower CV risk in Psoriasis and Psoriatic Arthritis

Join RheumNow for a live recap of Day 1 of ACR Convergence 2026. Our expert faculty will highlight key abstracts, emerging research, and clinical insights from the day’s sessions, offering perspective on what these findings may mean for rheumatology practice.

Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA.